Clinical Trials Browser

Phase 2 × Completed × Ado-Trastuzumab Emtansine × Clear all

Breast Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast

Breast Neoplasms

NCT01975142 2025-11-24

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

Phase 2 Completed

155 enrolled

Breast

Breast Neoplasms

NCT01565200 2025-03-31

ZEPHIR

Phase 2 Completed

90 enrolled

Breast

Breast Neoplasms

NCT04632992 2025-01-08

MyTACTIC

Phase 2 Completed

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

NCT03530696 2024-08-13

T-DM1

Phase 2 Completed

55 enrolled 19 charts

Breast

Breast Neoplasms

NCT02448420 2024-04-18

PATRICIA II

Phase 2 Completed

73 enrolled

Breast

Breast Neoplasms

NCT01904903 2022-05-10

SAFE-HEaRt

Phase 2 Completed

31 enrolled 12 charts

Breast

HER2 Positive Breast Cancer

NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Phase 2 Completed

62 enrolled 15 charts

CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

NCT02073487 2021-09-22

TEAL

Phase 2 Completed

32 enrolled 7 charts

Breast

Breast Neoplasms

NCT01835236 2021-03-30

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Phase 2 Completed

208 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02924883 2021-02-17

KATE2

Phase 2 Completed

202 enrolled 21 charts

Breast

Breast Neoplasms

NCT02999672 2019-08-28

KAMELEON

Phase 2 Completed

20 enrolled 14 charts

GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT02289833 2019-08-07

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

49 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00679211 2017-03-31

A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

Phase 2 Completed

110 enrolled 12 charts

Breast

Breast Neoplasms

NCT01196052 2014-10-06

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

Phase 2 Completed

153 enrolled 11 charts

Breast

Breast Neoplasms

NCT00679341 2014-01-09

A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

Phase 2 Completed

137 enrolled 13 charts

Breast

Breast Neoplasms

NCT00943670 2013-05-27

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Phase 2 Completed

51 enrolled 27 charts

Breast

Breast Neoplasms

NCT00509769 2013-04-02

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Phase 2 Completed

112 enrolled 10 charts

Breast

Breast Neoplasms

Clinical Trials

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

ZEPHIR

MyTACTIC

T-DM1

PATRICIA II

SAFE-HEaRt

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

TEAL

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

KATE2

KAMELEON

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer